European Journal of Haematology最新文献_第2页

Daratumumab for Posttransplant Autoimmune Hemolytic Anemia. 达拉单抗用于移植后自身免疫性溶血性贫血。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-17 DOI: 10.1111/ejh.14411

Yaqeen Abduallah, Michael Kennah, Connor Prince, Ashish Masurekar, Natasha Kekre, Ram Vasudevan Nampoothiri

引用次数: 0

Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis. 成人继发性噬血细胞性淋巴组织细胞病患者生存的临床病理预后模型。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-15 DOI: 10.1111/ejh.14412

Pongthep Vittayawacharin, Benjamin J Lee, Ghayda' E'leimat, Yen Cao, Jack Reid, Ashley Gamayo, Sherif Rezk, Elizabeth A Brem, Lisa X Lee, Piyanuch Kongtim, Stefan O Ciurea

{"title":"Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis.","authors":"Pongthep Vittayawacharin, Benjamin J Lee, Ghayda' E'leimat, Yen Cao, Jack Reid, Ashley Gamayo, Sherif Rezk, Elizabeth A Brem, Lisa X Lee, Piyanuch Kongtim, Stefan O Ciurea","doi":"10.1111/ejh.14412","DOIUrl":"https://doi.org/10.1111/ejh.14412","url":null,"abstract":"Background: Data on bone marrow (BM) findings in secondary hemophagocytic lymphohistiocytosis (sHLH) and their association with overall survival (OS) are limited.Objectives: This study aimed to develop a prognostic model incorporating BM findings and clinico-laboratory factors affecting OS.Methods: We retrospectively evaluated 50 adults with sHLH and developed a clinicopathological prognostic model based on survival-associated factors.Results: Most patients demonstrated normocellular BM (46.3%) and mild hemophagocytic activity (44.2%). Factors associated with survival in multivariable analyses (MVA) were age above 70 years (hazard ratio [HR] 3.89, p = 0.016), infection-related (HR 4.62, p = 0.006), hemoglobin < 7 g/dL (HR 5.21, p < 0.001), and hypocellular marrow (HR 3.07, p = 0.04). A clinicopathological HLH risk model assigned 1 point to each MVA-identified survival factor, categorizing patients into low- (score 0-1), intermediate- (score 2-3), and high-risk (score 4) groups. The 6-month OS from bootstrapping internal validation among the low-, intermediate-, and high-risk groups were 84.2%, 55.6% (p < 0.001) and 7.7% (p < 0.001), respectively. The area under the receiver operating characteristic curve (AuROC) was 0.87.Conclusions: This model stratified sHLH patients into three risk groups with distinct survival outcomes, potentially guiding future therapy.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma. 达拉图单抗治疗多发性骨髓瘤患者报告的生存和不良事件的预测和预后意义。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-14 DOI: 10.1111/ejh.14410

Ahmad Y Abuhelwa, Sara A Almansour, Ethan Basch, Humaid O Al-Shamsi, Ziad Abuhelwa, Yasser Bustanji, Mohammad H Semreen, Zelal Kharaba, Salma M Ali, Rawan Mohamed, Ganessan Kichenadasse, Ross A McKinnon, Michael J Sorich, Karem H Alzoubi, Ashley M Hopkins

{"title":"Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.","authors":"Ahmad Y Abuhelwa, Sara A Almansour, Ethan Basch, Humaid O Al-Shamsi, Ziad Abuhelwa, Yasser Bustanji, Mohammad H Semreen, Zelal Kharaba, Salma M Ali, Rawan Mohamed, Ganessan Kichenadasse, Ross A McKinnon, Michael J Sorich, Karem H Alzoubi, Ashley M Hopkins","doi":"10.1111/ejh.14410","DOIUrl":"https://doi.org/10.1111/ejh.14410","url":null,"abstract":"Objectives: Patient-reported outcomes (PROs), including physical function, have predictive potential for survival but remain underexplored in multiple myeloma (MM). This study evaluates the predictive and prognostic value of PROs for treatment outcomes in MM patients on daratumumab-based therapy and evaluates physical function versus ECOG Performance Status as a potential treatment-effect modifier.Methods: Data was pooled from randomized trials (MAIA, POLLUX, CASTOR) that collected pretreatment PROs using EORTC QLQ-C30. Cox models and logistic regression examined associations between PROs and overall survival (OS), progression-free survival (PFS) and grade ≥ 3 adverse events. Physical function versus ECOG-PS was examined as a treatment effect modifier for daratumumab versus non-daratumumab therapies.Results: Among 1804 patients, 1535 (85%) had pretreatment PROs. Physical function, global health, and fatigue were most prognostic for survival and adverse events. Physical function provided independent prognostic value beyond ECOG-PS and was predictive of treatment effect. Low physical function patients experienced greater OS treatment benefit (adjusted HR (aHR) [95% CI] 0.53 [0.40-0.70], p interaction = 0.02) and PFS (aHR [95% CI] 0.30 [0.30-0.48], p interaction = 0.03) from daratumumab versus high-physical function (OS aHR 0.86 [0.62-1.19], PFS aHR 0.53 [0.42-0.67]).Conclusion: Physical function is a predictive and prognostic marker that complements ECOG-PS, supporting its use in informing therapy decisions for daratumumab-based treatments.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CLLAF SCORE-A New Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating First- and Second-Generation BTK Inhibitor Therapy. CLLAF评分——一种新的风险评分，用于预测首次接受第一代和第二代BTK抑制剂治疗的CLL患者心房颤动。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-12 DOI: 10.1111/ejh.14400

Tamar Tadmor, Guy Melamed, Hilel Alapi, Lior Rokach

{"title":"CLLAF SCORE-A New Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating First- and Second-Generation BTK Inhibitor Therapy.","authors":"Tamar Tadmor, Guy Melamed, Hilel Alapi, Lior Rokach","doi":"10.1111/ejh.14400","DOIUrl":"https://doi.org/10.1111/ejh.14400","url":null,"abstract":"Background: One of the limiting toxicities of BTKi is the development of atrial fibrillation (AF), with an incidence of 3%-16%.Aim: This study aimed to identify patients with chronic lymphocytic leukemia (CLL) starting both first- and second-generation BTKis who are at high risk of developing AF using a machine learning approach.Methods: The CLL cohort is based on data obtained from electronic medical records from Maccabi, the second-largest healthcare organization in Israel. The optimal scoring model was determined using the Risk-calibrated Supersparse Linear Integer Model (RiskSLIM) algorithm.Results: A total of 3964 patients with a CLL diagnosis were available in the database. Of these, 208 patients started BTKi during the study period (125 on ibrutinib and 83 on acalabrutinib), and 16 patients developed AF during follow-up. In addition to well-established factors such as age, sex, and hypertension, the algorithm detected other factors associated with a high risk for AF: type of BTKi used, low eGFR, elevated absolute monocytes (> 1100/μL), elevated CRP, elevated CK, and elevated B2MG (> 2.5 mg/L). Based on the total AF-free survival (AFS), we identified three main risk groups: low (0-6), intermediate (7-11) and high (≥ 12). The median AF-free survival (AFS) was 28 and 56 months for the high-risk and intermediate-risk groups, respectively, and was not reached for the low-risk group. The difference between the groups was statistically significant (p = 0.0013).Conclusion: Our novel score has a high concordance index for predicting the development of AF in patients with CLL treated with first- and second-generation BTKis. It combines age, sex, medical history, and laboratory tests associated with inflammatory status and disease burden and can be applied in clinical settings worldwide.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy. 针对慢性淋巴细胞白血病的免疫微环境：一种不断发展的治疗策略。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-11 DOI: 10.1111/ejh.14408

Clement Chung, David Doan

{"title":"Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy.","authors":"Clement Chung, David Doan","doi":"10.1111/ejh.14408","DOIUrl":"https://doi.org/10.1111/ejh.14408","url":null,"abstract":"Although small molecule inhibitors that target the aberrant signaling pathways and molecular defects of chronic lymphocytic leukemia (CLL) result in improved survival benefits vs. traditional chemoimmunotherapy or chemotherapy, treatment resistance may result later, reflecting the intrinsic tumor heterogeneity, persistence of the leukemic clone, and presence of the tumor microenvironment, which supports the survival of the disease clone. Patients with CLL have immune-related abnormalities in T lymphocyte subset composition, immune synapse formation, and other immune dysregulations. Cellular interactions between the disease clone and its microenvironment provide therapeutic opportunities to target these tumor pathogenesis pathways, potentially improving the patient's immune functions and clinical outcomes of targeted therapies. At present, despite the lack of response of immune checkpoint inhibitors in CLL, they showed promising efficacy in patients with Richter transformation. Together with CD19-targeted chimeric antigen receptor-modified T cell (CAR-T) therapy, novel bispecific antibodies and other immunotherapies are being investigated to improve survival outcomes for patients with relapsed or refractory (R/R) CLL, as exemplified by epcoritamab, a bispecific antibody that recently demonstrated initial efficacy in R/R CLL and in patients in high-risk CLL subgroups, including those with TP53 aberrations and unmutated genes that encode immunoglobulin variable heavy chain region (IGHV). Furthermore, to address the immune escape of cancer cells and issues that impact the durability of single-targeted T cell-redirected therapies, novel strategies such as trispecific antibodies and combination therapies are being investigated to increase tumor specificity or immune cell activation. In summary, there is emerging evidence that immunotherapies may counteract the immunosuppressive microenvironment of CLL, improve clinical responses, decrease the risk of infection, and overcome treatment resistance.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group (FBMTG). 持续给药达沙替尼对BCR::ABL1急性淋巴母细胞白血病患者预后的临床影响：福冈血液和骨髓移植组（FBMTG）进行的前瞻性MRD2014研究结果

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-07 DOI: 10.1111/ejh.14407

Koji Nagafuji, Yoshikiyo Ito, Toshihiro Miyamoto, Tetsuya Eto, Tomohiko Kamimura, Koji Kato, Yasuhiko Miyazaki, Atsuhi Wake, Kentaro Kohno, Ken Takase, Yutaka Imamura, Naoyuki Uchida, Kazuki Tanimoto, Noriaki Kawano, Toshiro Kurokawa, Yukio Kondo, Tomoaki Fujisaki, Junichi Tsukada, Koji Yonemoto, Koichi Akashi

{"title":"Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group (FBMTG).","authors":"Koji Nagafuji, Yoshikiyo Ito, Toshihiro Miyamoto, Tetsuya Eto, Tomohiko Kamimura, Koji Kato, Yasuhiko Miyazaki, Atsuhi Wake, Kentaro Kohno, Ken Takase, Yutaka Imamura, Naoyuki Uchida, Kazuki Tanimoto, Noriaki Kawano, Toshiro Kurokawa, Yukio Kondo, Tomoaki Fujisaki, Junichi Tsukada, Koji Yonemoto, Koichi Akashi","doi":"10.1111/ejh.14407","DOIUrl":"https://doi.org/10.1111/ejh.14407","url":null,"abstract":"Aim: To assess the efficacy of continuous dasatinib in improving outcomes for adult patients with BCR::ABL1 ALL.Methods: The prospective, multicenter ALL/MRD2014 trial introduced a modified protocol compared to the MRD2008 trial, incorporating continuous dasatinib use and reduced chemotherapy intensity.Results: Among the 164 adult ALL patients enrolled (2014-2019), 61 were Philadelphia-positive (Ph+) (median age 50 years; 38 males, 23 females). Post-induction, 96.7% achieved complete remission (CR). The 3-year event-free survival (EFS) and overall survival (OS) were 51% and 76%, respectively. Patients undergoing allo-HSCT in CR1 had improved outcomes, with a 3-year EFS of 64% and OS of 87%. MRD-negative patients before transplantation exhibited superior survival (EFS: 71% vs. 29%; OS: 94% vs. 57%). Comparison with the MRD2008 trial revealed similar outcomes, with the MRD2014 trial achieving a 3-year EFS of 51% and OS of 76% vs. 52% and 84% in MRD2008. Although not statistically significant, the MRD2014 trial showed trends of increased relapse (CIR: 39% vs. 26%, p = 0.305) and reduced non-relapse mortality (NRM: 10% vs. 21%, p = 0.181).Conclusion: The ALL/MRD2014 trial underscores the importance of MRD status and allo-HSCT in Ph+ ALL. Continuous dasatinib-based regimens offer favorable outcomes in MRD-negative patients.Trial registration: This study was registered with the UMIN Clinical Trials Registry (UMIN-CTR), number UMIN000012382.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Further Reflections on 6-MP Adherence and Habit Strength: The Impact of Dose Adjustment Complexity and Caregiver Burden. 对6-MP依从性和习惯强度的进一步思考：剂量调整复杂性和护理人员负担的影响。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-07 DOI: 10.1111/ejh.14406

Jiamin Lu, Hui Wu, Wei Wei

引用次数: 0

Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies. 成人患者复发或难治性b细胞急性淋巴细胞白血病的治疗策略：优化单克隆抗体的使用。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-06 DOI: 10.1111/ejh.14405

Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile

{"title":"Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies.","authors":"Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile","doi":"10.1111/ejh.14405","DOIUrl":"https://doi.org/10.1111/ejh.14405","url":null,"abstract":"The treatment landscape for relapsed or refractory acute lymphoblastic leukemia (RR ALL) has evolved significantly with the introduction of monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin. These agents have demonstrated remarkable efficacy, achieving high response rates and minimal residual disease (MRD) negativity. However, the optimal selection, sequencing, and integration of monoclonal antibodies and other modalities like standard chemotherapy or chimeric antigen receptor T-cell therapy remain areas of active investigation. The absence of direct comparative studies has led to reliance on indirect analyses, which provide conflicting results regarding the relative benefits of inotuzumab and blinatumomab. While inotuzumab is preferred in high-disease-burden settings due to its cytoreductive capabilities, blinatumomab shows superior performance in low-disease-burden settings by leveraging preserved T-cell function. Sequential and combination approaches, such as induction with inotuzumab followed by blinatumomab consolidation, may optimize outcomes, particularly for patients undergoing subsequent allogeneic stem cell transplantation (alloSCT). The interval between inotuzumab and alloSCT is critical to mitigate the risk of veno-occlusive disease (VOD). Despite these advances, the prognosis for patients with high-risk genetic lesions, such as TP53 mutations, remains poor, underscoring the need for innovative therapeutic strategies. As monoclonal antibodies increasingly move into frontline therapy, their role in relapse settings must be redefined. Future research should focus on unraveling the molecular underpinnings of resistance and refining treatment paradigms to improve survival and quality of life for patients with RR ALL.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic Mutations Driving Aplastic Anemia: A Focus on Key Allelic Changes. 基因突变驱动再生障碍性贫血：对关键等位基因变化的关注。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-04 DOI: 10.1111/ejh.14399

Fabiana Burceaga, Ayline Cárdenas, Jessica Ortega, Eduardo Galván

{"title":"Genetic Mutations Driving Aplastic Anemia: A Focus on Key Allelic Changes.","authors":"Fabiana Burceaga, Ayline Cárdenas, Jessica Ortega, Eduardo Galván","doi":"10.1111/ejh.14399","DOIUrl":"https://doi.org/10.1111/ejh.14399","url":null,"abstract":"Aplastic Anemia (AA) is a rare blood disorder where the bone marrow fails, leading to pancytopenia. Most of the time it is idiopathic; however, it can also be caused by drugs, radiation, infections, or genetic issues. Recent molecular research has revealed that specific mutations in the Human Leukocyte Antigen (HLA) genes play a pivotal role in AA's pathogenesis, clinical presentation, and therapeutic response. Notably, mutations in the HLA have emerged as crucial in the disease's molecular pathway. These mutations interfere with HLA coding. Specifically, cytotoxic CD8+ T cells become aberrantly activated and undergo clonal expansion that continues to attack the hematopoietic stem cells (HSCs). Advances in genetic screening allow the detection of these specific mutations, enabling a more personalized treatment approach, considering immunosuppressive therapies (IST) or bone marrow transplantation. This review is based on the role of the most common HLA genotype (HLA-B*40:02 and HLA-B*14:02) and somatic mutations (TERT, TERC, ASXL1, and DNMT3A) in contributing to immune dysregulation and the clinical presentation of AA according to the severity, treatment response, and prognosis depending on the mutation presented.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TP53-Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges. tp53突变的急性髓性白血病：治疗和挑战的回顾。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2025-03-04 DOI: 10.1111/ejh.14404

Bipin Ghimire, Markie Zimmer, Vijayalakshmi Donthireddy

{"title":"TP53-Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges.","authors":"Bipin Ghimire, Markie Zimmer, Vijayalakshmi Donthireddy","doi":"10.1111/ejh.14404","DOIUrl":"https://doi.org/10.1111/ejh.14404","url":null,"abstract":"Patients with acute myeloid leukemia (AML) harboring mutations in TP53 (TP53-MT) have poor responses to current therapies and unfavorable prognoses. Despite the recognition of variant TP53 as an adverse feature of AML, an optimal treatment regimen has not yet been established, underlining a critical need for new, more effective therapeutic combinations and novel treatments. We present the case of a patient with TP53-MT AML and marked myelodysplasia who developed primary refractory disease after induction therapy with the intensive chemotherapy regimen of liposomal daunorubicin and cytarabine. Our patient's optimal response to second induction chemotherapy with FLAG-Ida prompted an exploration of established and investigational treatment regimens for this specific high-risk AML subtype. Therefore, we performed a comprehensive literature review of findings from studies exploring AML therapies, focusing on outcomes for patients with TP53-MT AML. The summary provided here reveals the complexity of defining the therapeutic responses of patients with the heterogeneous TP53-MT genetic background and the challenges in treating this high-risk form of AML. Future work must continue to investigate novel therapies and combinations to improve patient outcomes in this vulnerable population.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0